CHOC Children's Hospital Research Institute, University of California, Irrine, Orange, 92868, USA.
Curr Stem Cell Res Ther. 2012 Jan;7(1):2-14. doi: 10.2174/157488812798483449.
Recent studies have shown that treatments involving injection of stem cells into animals with damaged cardiac tissue result in improved cardiac functionality. Clinical trials have reported conflicting results concerning the recellularization of post-infarct collagen scars. No clear mechanism has so far emerged to fully explain how injected stem cells, specifically the commonly used mesenchymal stem cells (MSC) and endothelial precursor cells (EPC), help heal a damaged heart. Clearly, these injected stem cells must survive and thrive in the hypoxic environment that results after injury for any significant repair to occur. Here we discuss how ischemic preconditioning may lead to increased tolerance of stem cells to these harsh conditions and increase their survival and clinical potential after injection. As injected cells must reach the site in numbers large enough for repair to be functionally significant, homing mechanisms involved in stem cell migration are also discussed. We review the mechanisms of action stem cells may employ once they arrive at their target destination. These possible mechanisms include that the injected stem cells (1) secrete growth factors, (2) differentiate into cardiomyocytes to recellularize damaged tissue and strengthen the post-infarct scar, (3) transdifferentiate the host cells into cardiomyocytes, and (4) induce neovascularization. Finally, we discuss that tissue engineering may provide a standardized platform technology to produce clinically applicable stem cell products with these desired mechanistic capacities.
最近的研究表明,将干细胞注入受损心肌组织的动物体内的治疗方法可改善心脏功能。临床试验报告了关于梗死胶原瘢痕再细胞化的相互矛盾的结果。迄今为止,尚无明确的机制可以完全解释注射的干细胞(特别是常用的间充质干细胞[MSC]和内皮祖细胞[EPC])如何帮助修复受损的心脏。显然,这些注入的干细胞必须在损伤后产生的缺氧环境中存活并茁壮成长,才能发生任何有意义的修复。在这里,我们讨论了缺血预处理如何导致干细胞对这些恶劣条件的耐受性增加,并增加了它们在注射后的存活和临床潜力。由于注入的细胞必须达到足以进行功能修复的数量,因此还讨论了涉及干细胞迁移的归巢机制。我们回顾了干细胞到达其靶目标后可能采用的作用机制。这些可能的机制包括注入的干细胞(1)分泌生长因子,(2)分化为心肌细胞以再细胞化受损组织并增强梗死瘢痕,(3)将宿主细胞转分化为心肌细胞,以及(4)诱导血管生成。最后,我们讨论了组织工程可能为产生具有这些所需机制能力的临床适用的干细胞产品提供标准化的平台技术。